Type of business Nonprofit organization | Purpose Open science | |
 | ||
Affiliations Fred Hutchinson Cancer Research Center Affiliation Fred Hutchinson Cancer Research Center Similar Fred Hutchinson Cancer R, Prize4Life, Institute for Systems Biology, Allen Institute for Brain Sci, International Society for Computat Profiles | ||
Dr stephen friend sage bionetworks darpa bit keynote speaker
Sage Bionetworks is a nonprofit organization in Seattle that promotes open science and patient engagement in the research process. It is housed in the campus of Fred Hutchinson Cancer Research Center and led by Lara Mangravite. It was co-founded by Stephen Friend and Eric Schadt.
Contents
- Dr stephen friend sage bionetworks darpa bit keynote speaker
- Michael kellen sage bionetworks on aws
- Open science
- Research
- History
- References
Michael kellen sage bionetworks on aws
Open science
Sage Bionetworks is notable for being an early advocate of open science. The company operates a software platform for collaborative data analysis called Synapse that allows researchers to work together on data curation and computational modeling asynchronously in a manner inspired by GitHub. Synapse also serves as the software infrastructure for running computational challenges. Sage is also developing a citizen-science platform called Bridge.
Research
The bulk of Sage's scientific results emerge from cancer and neurosciences, with notable contributions to the Cancer Genome Atlas Pan-Cancer project. Another Sage initiative, The Resilience Project describes itself as a search for individuals who have genetic changes expected to cause severe illness but who remain perfectly healthy. The hope is to yield insight into factors that protect these individuals from disease.
History
Sage Bionetworks was founded in 2009 as a spinout of Merck & Co., who released software, hardware, intellectual property, and staff connected to its Rosetta Inpharmatics unit. A donation from Quintiles provided early funding.
In March 2011 Sage partnered with CHDI Foundation to develop computer simulations for studying Huntington's disease. At the same time Sage also announced a partnership with Takeda Pharmaceutical Company wherein Sage would do research to identify biological targets for central nervous system diseases.
In February 2013, Sage Bionetworks merged with the Dialogue on Reverse Engineering Assessment and Methods (DREAM) project.